Psychiatric side effects debated.

There were many questions and much word during the webcast on the potency for psychiatric side effects with acomplia. Of patients on rimonabant in COMPOSITION, 5.8% experienced symptoms of depressed mood, compared with 0.7% of those on medicinal drug, Rosenstock said, but he cautioned that this was a broad class. There were four dropouts among patients on rimonabant due to psychiatric causes, he noted, trio with "mood disorders" and one with sadness. Also, in SONG, patients with a continuum of psychiatric events were not excluded from the proceedings as was the case with the RIO studies, he noted.
Dr Luc van Gaal (University Healthcare facility Antwerp, Belgium) reminded attendees that the European labeling recommends that acomplia not be used in patients with subject economic crisis or those requiring antidepressant drug.
Other questions included an questioning as to how long rimonabant can be taken for. Dr André J Scheen (University of Metropolis, Belgium) said: "Strictly utterance, we can use it for one year in diabetics and two period of time in others," but in world there is probably no account why it cannot be used long-term in patients who respond to it, he noted, adding, "We will know more in a few gathering when the results of the CRESCENDO endeavour, perception at cardiovascular end points in 17 000 patients taking the drug for four or five days, become available."